Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

STADA appoints Nigel Stephenson to lead UK business

STADA has appointment Nigel Stephenson as General Manager UK with effect from 1 August 2023.

Based in Huddersfield, UK, Stephenson will report directly to STADA’s Head of Western Europe and Germany, Stephan Eder.


He will take over from Rudolf Bär, who has successfully led the UK business for almost one year in addition to his responsibilities for STADA’s Mid-Sized European Markets.|

A dynamic and modern commercial leader with extensive experience in sales and marketing across Western, Central and Eastern Europe, and the UK in leading pharmaceutical, consumer healthcare and fast-moving consumer goods companies.

He joins STADA from consumer healthcare leader Haleon, where he most recently served as General Manager Switzerland.

“With his strong people and results orientation, along with deep purpose-driven engagement, Nigel will support our UK team in realizing its full potential through innovative and inclusive leadership,” stated Eder.

“Building on the strong progress made under Rudolf Bär over the past year, I am confident that Nigel will lead our team in the UK to deliver strong, sustainable growth.”

Stephenson started his career as part of the IBM Global Leaders Program in the US. He then worked for more than 9 years at Procter & Gamble, spanning local and regional marketing roles for key brands such as Ariel, before subsequently taking over cross-regional and global marketing responsibilities.

He continued his personal growth at two renowned global healthcare companies, Novartis and GSK, developing from leading regional and global marketing roles in Switzerland and Poland to general management positions for Romania & Moldova and Switzerland. In his last position as General Manager Switzerland at Haleon, Nigel successfully demonstrated exceptional leadership skills and achieved significant growth for the organization.

“I am looking forward to further strengthening the STADA growth mindset in UK, working on iconic brands such as Covonia, Care, Cetraben, Hedrin, Oilatum and Zoflora, as well as our growing Generics and Specialty portfolios in the UK,” Stephenson commented.

“Based on the strong commercial performance, product launches and employee engagement achieved under Rudolf’s leadership, I am sure that our high-performance team will continue to deliver sustainable growth and to outperform the industry.”

More For You

NHS to invest millions to boost enhanced treatment for sickle cell patients

Approximately 17,000 people live in England with sickle cell disease

Pic credit: istock

NHS to invest millions to boost enhanced treatment for sickle cell patients

The Department of Health and Social Care has announced that it will invest £9 million towards the treatment of sickle cell patients.

Approximately 17,000 people live in England with sickle cell disease. Nearly 250 new cases of this inherited blood disorder is reported annually.

Keep ReadingShow less
NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients

An estimated 6,000 cases of multiple myeloma is diagnosed in the UK each year.

Pic credit: istock

NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients


NHS England has become the first in the world to introduce a ‘trojan horse’ therapy for the victims of blood cancer with the ground-breaking treatment slowing down the illness three-times more than existing treatments.

Keep ReadingShow less
Call to improve inclusivity in clinical research

Ethnic minority adults continue to be underrepresented in clinical trials.

iStock

Call to improve inclusivity in clinical research

A NEW report has called for the participation of a wide range of diverse communities in clinical research to make sure that the medicines meet the needs of the UK's increasingly diverse population.

The report ‘Achieving inclusivity in clinical research’, prepared by the Association of the British Pharmaceutical Industry (ABPI) and the Association of Medical Research Charities (AMRC), highlights the long-standing challenges in ensuring diversity in clinical trials.

Keep ReadingShow less
Pharmacy students Learning Support Fund

Pharmacy students will be included in the Travel and Dual Accommodation Expenses section of the NHS Learning Support Fund.

iStock

Pharmacy students to have access to Learning Support Fund

FOR the first time in England, pharmacy students will be eligible to reimburse travel and accommodation costs while attending placements.

The Department of Health and Social Care confirmed that pharmacy students would finally be included in the Travel and Dual Accommodation Expenses (TDAE) section of the NHS Learning Support Fund (LSF).

Keep ReadingShow less
NHS for robotic surgery

Patients undergoing robotic surgery are able to recover quicker and be discharged sooner.

Pic credit: iStock

NHS pushes for robotic surgery to reduce waiting time, improve outcomes

The NHS is planning to step up robotic surgery over the next decade to reduce waiting time, help in the speed of recovery of patients, and shorter hospital stay.

As per the NHS projections, the number is expected to zoom from 70,000 in 2023/24 to half a million by 2035.

Keep ReadingShow less